Alkem says US FDA has accepted plan to fix Ankaleshwar API plant

By Gareth Macdonald

- Last updated on GMT

iStock/Singh_Lens
iStock/Singh_Lens

Related tags Food and drug administration

Alkem Laboratories Ltd says the US FDA has accepted its plan to bring its API plant in Ankaleshwar, India up to code.

The Indian drug manufacturer announced it had received an Establishment Inspection Report (EIR) last Wednesday​, explaining the US regulator has closed its investigation after reviewing its corrective and preventive action (CAPA) plan.

The US Food and Drug Administration (FDA) identified problems at the Gujarat plant during an inspection in December​.  

Alkem owns and operates 14 manufacturing facilities in India and two in the US. Its API plants are in Ankleshwar and Mandwa.

The EIR comes weeks​ after the US FDA issued Alkem with a Form 483 after an inspection at its facility in Himachal Pradesh.

The facility – in Baddi - was visited by an inspection team between March 2 and 10 resulting in a report containing three observations.

Alkem declined to share details of its remediation plan when contacted by in-Pharmatechnologist.com.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars